The PREVER Study

Abstract

The PREVER study addressed two open issues in the management of prehypertension and hypertension. The PREVER-PREVENTION trial evaluated the effectiveness of a low dose of chlorthalidone with amiloride in the prevention of hypertension and target organ damage. The PREVER-TREATMENT trial compared the BP-lowering effect of diuretics and angiotensin receptor blockers and their BP effects on surrogate outcomes. Both were randomized, parallel, double-blind, controlled trials, conducted in parallel in 21 Brazilian academic centers, with 730 and 655 participants, respectively. Participants were eligible if remained with prehypertension or Stage-1 hypertension, respectively, after 3 months of lifestyle intervention. The incidence of hypertension was significantly lower along 18 months of follow-up in participants allocated to diuretics compared to placebo (hazard ratio 0.56, 95% CI 0.38–0.82). Left ventricular mass assessed by ECG indices decreased to a greater extent in participants allocated to diuretic.